I don’t think so—hostile takeovers in the biotech industry are extremely rare. A takeover by ABBV, specifically, can be ruled out since it would never pass muster with antitrust regulators.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”